Patients with beta-thalassemia able to access first approved gene therapy
A gene therapy drug approved by the U.S. Food and Drug Administration (FDA) has been…
August 18, 2022 - 3 minutes
Bluebird Bio
A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
CAR-T therapy has been hailed as a cure for cancer, but what really is this…
October 11, 2021 - 10 minutes
Bluebird Bio Withdrawal Raises Gene Therapy Doubts in Europe
Last month, the US firm bluebird bio abandoned the sale of its gene therapy Zynteglo…
May 4, 2021 - 5 minutes
Bluebird Bio Launches First Gene Therapy for Beta Thalassemia in Germany
The US company bluebird bio has launched the first gene therapy for the blood disorder…
January 14, 2020 - 3 minutes
Novo Nordisk and Bluebird Bio to Treat Hemophilia with Gene Editing
The Danish big pharma Novo Nordisk has joined forces with the US gene therapy company…
October 9, 2019 - 1 minute
First Gene Therapy for Beta Thalassemia Will Cost Over €1.5M
Zynteglo, a gene therapy developed by the US company bluebird bio for the treatment of…
June 14, 2019 - 1 minute
First Gene Therapy for Beta Thalassemia Approved in Europe
The US biotech company bluebird bio has obtained EU conditional market approval for a gene…
June 4, 2019 - 3 minutes
Gene Therapy For Beta-Thalassemia Could Eliminate Need for Transfusions
Bluebird bio has obtained results from two clinical studies showing its new gene therapy could eliminate…
April 20, 2018 - 2 minutes
Scottish Biotech and Bluebird Bio to Develop Next Generation CAR-T Cells
TC Biopharm has scored a deal with bluebird bio for the development of the next…
December 7, 2017 - 2 minutes
The Largest Deals, Fundraising and Exits of 2016 in European Biotech
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a…
December 26, 2016 - 5 minutes
What do the CAR-T Patient Deaths Mean for the Future of the Field?
Juno’s JCAR015 study came to a halt for the second time this year after two…
December 14, 2016 - 7 minutes
UniQure’s cure for rare Lysosomal disease ready for phase III trial
UniQure from the Netherlands has promising results for its enzyme replacement therapy phase Ib/II trial…
September 22, 2015 - 3 minutes
